Rockville, MD – The treatment of patients with Chronic Lymphocytic Leukemia (CLL) has shifted substantially in the past five years from intravenous treatments (IV) to oral oncolytics. With this transition towards oral therapies, cancer care teams face different challenges such as medication adherence, polypharmacy, financial toxicity, and interruptions in continuity of care due to oral prescriptions and outside pharmacies. As the use of oral oncolytics increases, cancer programs must prepare for the successful implementation of oral therapy programs.
Effective integration of oral oncolytics into community practice depends on multidisciplinary team collaboration, assessment of patient specific CLL treatment goals, accurate and efficient medication dispensing, patient education, medication adherence, and thorough data capture.
The Association of Cancer Care Centers (ACCC) today announced the release of new resources aimed at supporting cancer care teams in the effective integration of oral oncolytics into the CLL cancer care continuum.
Resources include:
Resources are available on ACCC’s website, found here.
“Outcomes for patients with CLL have drastically improved with advances in oral therapies. A collaborative group of experts within ACCC evaluated nationwide, best practices for optimizing care delivery with oral therapies for CLL. Checkout these resources!”
— Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, Director of Pharmacy at Minnesota Oncology, and Assistant Professor of Pharmacy at the Mayo Clinic College
This project was made possible by support from AbbVie.
January 21, 2026
October 30, 2025
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
